Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05310448 · ClinicalTrials.gov registry record · NA
Tumor Treating Fields for the Treatment of Brainstem Gliomas
A NA study of Glioma, sponsored by Emory University.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT05310448 is a NA study of Glioma that is actively recruiting participants, run by Emory University. The registered enrollment target is 10 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05310448, a NA study of Glioma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with cancer cell division. TTFields may prevent growth or decrease size of gliomas in patients
Conditions Studied
Interventions
- DEVICE Optune device
Study Locations (3)
Georgia
- Emory Proton Therapy Center - Atlanta
- Emory University/Winship Cancer Institute - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2027-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05310448
The ClinicalTrials.gov registry entry for NCT05310448 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (95% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which Optune device is the first listed.
NCT05310448 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05310448 about?
NCT05310448 is a clinical study titled "Tumor Treating Fields for the Treatment of Brainstem Gliomas". This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with can...
What is the current status of trial NCT05310448?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2022-05-11. Estimated completion is 2027-05-01.
What conditions does trial NCT05310448 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT05310448?
The interventions under investigation include: Optune device (DEVICE).
Who is sponsoring clinical trial NCT05310448?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05310448 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ASCENT Intervention for Brain Tumor Patients
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
-
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.